This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Relationship of Pretreatment Homovanillic Acid to Antidepressant Response

Robert M. Post, MD; Robert H. Gerner, MD; John S. Carman, MD; J. Christian Gillin, MD; David C. Jimerson, MD; Frederick K. Goodwin, MD; William E. Bunney, Jr, MD

Arch Gen Psychiatry. 1978;35(5):609-615.

Abstract
• Piribedil, a compound that stimulates dopamine receptors in a relatively specific fashion, was administered to 11 hospitalized depressed patients. The dopamine agonist significantly decreased rapid eye movement (REM) sleep and percent REM sleep and increased REM latency. Piribedil decreased the probenecid-induced accumulation of the dopamine metabolite homovanillic acid (HVA) in CSF. A range of mild to moderate antidepressant effects was noted; one patient worsened and one developed recurrent manic episodes. The degree of improvement in depression was negatively correlated with pretreatment values of HVA in CSF (r = —.66, p <.05). These data suggest that the heterogeneity of clinical response may be related to biological differences in depressed patients and that those with low initial dopaminergic function respond best to increased dopamine receptor stimulation.

Author Affiliations
From the Biological Psychiatry Branch (Drs Post, Gerner, Carman, Gillin, Jimerson, and Bunney), and the Clinical Psychobiology Branch (Dr Goodwin), National Institute of Mental Health, Bethesda, Md.

Footnotes
Accepted for publication Nov 22, 1977.

Reprint requests to National Institutes of Health, Bldg 10, Room 3S239, 9000 Rockville Pike, Bethesda, MD 20014 (Dr Post).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Role of Dopamine in the Pathophysiology of Depression
Dunlop and Nemeroff
Arch Gen Psychiatry 2007;64:327-337.
FULL TEXT  

What Is a "Mood Stabilizer"? An Evidence-Based Response
Bauer and Mitchner
Am. J. Psychiatry 2004;161:3-18.
ABSTRACT | FULL TEXT  

Adenosine A2A receptors and depression
El Yacoubi et al.
Neurology 2003;61:S82-87.
ABSTRACT | FULL TEXT  

Magnetic Resonance Imaging of the Caudate Nuclei in Depression: Preliminary Observations
Krishnan et al.
Arch Gen Psychiatry 1992;49:553-557.
ABSTRACT  

Bupropion in Depression: I. Biochemical Effects and Clinical Response
Golden et al.
Arch Gen Psychiatry 1988;45:139-143.
ABSTRACT  

Dopaminergic Effects of Carbamazepine: Relationship to Clinical Response in Affective Illness
Post et al.
Arch Gen Psychiatry 1986;43:392-396.
ABSTRACT  

Higher CSF Levels of HVA and 5-HIAA in Delusional Compared to Nondelusional Depression
Aberg-Wistedt et al.
Arch Gen Psychiatry 1985;42:925-926.
ABSTRACT  

Cerebral Metabolic Rates for Glucose in Mood Disorders: Studies With Positron Emission Tomography and Fluorodeoxyglucose F 18
Baxter et al.
Arch Gen Psychiatry 1985;42:441-447.
ABSTRACT  

Growth Hormone and Prolactin Response to Apomorphine in Schizophrenia and the Major Affective Disorders: Relation to Duration of Illness and Depressive Symptoms
Meltzer et al.
Arch Gen Psychiatry 1984;41:512-519.
ABSTRACT  

Increased intracranial self-stimulation in rats after long-term administration of desipramine
Fibiger and Phillips
Science 1981;214:683-685.
ABSTRACT  

{beta}-Endorphin: Intravenous Infusion Causes Behavioral Change in Psychiatric Inpatients
Gerner et al.
Arch Gen Psychiatry 1980;37:642-647.
ABSTRACT